{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-24-000058","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2024-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.781594+00:00","generated_at":"2026-05-31T19:06:01.643375+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Salarius closes Phase 1/2 seclidemstat Ewing sarcoma trial; explores strategic alternatives","bullets":["Company terminates ongoing Phase 1/2 clinical trial evaluating seclidemstat for Ewing sarcoma to conserve cash.","Board of Directors continues exploring strategic alternatives focused on maximizing shareholder value.","Still supporting MD Anderson's sponsored trial of seclidemstat + azacitidine in MDS/CMML (on partial clinical hold after grade 4 adverse event).","Warns it may need to dissolve if unable to raise capital or complete a strategic transaction soon."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-24-000058","json":"https://secwatch.observer/filing/0001615219-24-000058.json","markdown":"https://secwatch.observer/filing/0001615219-24-000058.md","text":"https://secwatch.observer/filing/0001615219-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000058/0001615219-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521924000058/flks-20240719.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:06:01.643375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}